India · Delayed Price · Currency is INR Symbiotec Pharmalab Statistics
Total Valuation
NSE:SYMBIOTEC has a market cap or net worth of INR 69.28 billion. The enterprise value is 73.09 billion.
| Market Cap | 69.28B |
| Enterprise Value | 73.09B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
NSE:SYMBIOTEC has 64.26 million shares outstanding. The number of shares has increased by 5.75% in one year.
| Current Share Class | 64.26M |
| Shares Outstanding | 64.26M |
| Shares Change (YoY) | +5.75% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.93% |
| Owned by Institutions (%) | 40.97% |
| Float | 25.98M |
Valuation Ratios
The trailing PE ratio is 56.75.
| PE Ratio | 56.75 |
| Forward PE | n/a |
| PS Ratio | 7.97 |
| PB Ratio | 6.03 |
| P/TBV Ratio | 6.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 39.68 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 66.52 |
| EV / Sales | 8.41 |
| EV / EBITDA | 30.40 |
| EV / EBIT | 39.06 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of 0.34.
| Current Ratio | 0.92 |
| Quick Ratio | 0.42 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 1.63 |
| Debt / FCF | -7.65 |
| Interest Coverage | 7.79 |
Financial Efficiency
Return on equity (ROE) is 11.19% and return on invested capital (ROIC) is 9.37%.
| Return on Equity (ROE) | 11.19% |
| Return on Assets (ROA) | 6.96% |
| Return on Invested Capital (ROIC) | 9.37% |
| Return on Capital Employed (ROCE) | 14.93% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 4.54M |
| Profits Per Employee | 573,796 |
| Employee Count | 1,752 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.38 |
Taxes
In the past 12 months, NSE:SYMBIOTEC has paid 434.60 million in taxes.
| Income Tax | 434.60M |
| Effective Tax Rate | 28.34% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 6,922,043 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:SYMBIOTEC had revenue of INR 8.69 billion and earned 1.10 billion in profits. Earnings per share was 19.00.
| Revenue | 8.69B |
| Gross Profit | 5.25B |
| Operating Income | 1.87B |
| Pretax Income | 1.53B |
| Net Income | 1.10B |
| EBITDA | 2.39B |
| EBIT | 1.87B |
| Earnings Per Share (EPS) | 19.00 |
Balance Sheet
The company has 101.25 million in cash and 3.91 billion in debt, with a net cash position of -3.81 billion or -59.27 per share.
| Cash & Cash Equivalents | 101.25M |
| Total Debt | 3.91B |
| Net Cash | -3.81B |
| Net Cash Per Share | -59.27 |
| Equity (Book Value) | 11.50B |
| Book Value Per Share | 183.27 |
| Working Capital | -420.21M |
Cash Flow
In the last 12 months, operating cash flow was 1.75 billion and capital expenditures -2.26 billion, giving a free cash flow of -511.26 million.
| Operating Cash Flow | 1.75B |
| Capital Expenditures | -2.26B |
| Depreciation & Amortization | 519.13M |
| Net Borrowing | -1.56B |
| Free Cash Flow | -511.26M |
| FCF Per Share | -7.96 |
Margins
Gross margin is 60.39%, with operating and profit margins of 21.53% and 12.64%.
| Gross Margin | 60.39% |
| Operating Margin | 21.53% |
| Pretax Margin | 17.65% |
| Profit Margin | 12.64% |
| EBITDA Margin | 27.50% |
| EBIT Margin | 21.53% |
| FCF Margin | n/a |
Dividends & Yields
NSE:SYMBIOTEC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.75% |
| Shareholder Yield | -5.75% |
| Earnings Yield | 1.59% |
| FCF Yield | -0.74% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NSE:SYMBIOTEC has an Altman Z-Score of 1.4 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.4 |
| Piotroski F-Score | 5 |